CD5 and B-cell non-Hodgkin lymphoma: Studies of CD5 in some subsets of B-cell lymphomas, such as follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma, have demonstrated that the expression of CD5 is associated with a worse clinical outcome [20,21,22], whereas loss of CD5 expression is associated with better survival [23].